好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Cervical Stenosis on Multiple Sclerosis Lesion Distribution in the Spinal Cord
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-040

The purpose of this study is to use qualitative imaging analysis to determine if patients with multiple sclerosis (MS) have an increased likelihood of MS lesions at levels of existing cervical stenosis (CS).

The seminal paper on the relationship between MS and CS was published in 1957 by Brain and Wilkinson. Studies have since focused on whether surgical interventions are beneficial for MS patients, but only retrospective data of small cohorts exist, and their conclusions are mixed.

Forty-two comorbid MS and CS patients were identified via ICD codes and radiology reports. For each patient, axial and sagittal T2 sequences of cervical MRI scans were examined. The cord was split into 7 equal segments comprising the disc space and half of each adjacent vertebral body. Each segment was assessed for the presence of MS lesions and/or at least grade 2 CS by previously published criteria (Muhle et al, 1998). Lesions which were concerning for spondolytic-related signal change based on imaging characteristics were excluded (n=5, 5.3%). Clinical data was extracted from electronic medical records.

Average age at time of MRI was 56.6 +/- 9.2 years and average time with MS diagnosis was 13.3 +/- 9.0 years. The majority of patients suffered from RRMS (85.7%) and the F:M ratio was 3.6. Eighty-one percent of patients were on treatment at time of MRI, most often glatiramer acetate (33.3%). Spinal segments with at least grade 2 stenosis were significantly associated with the presence of an MS lesion in the same segment (χ2= 0.0120). This was also true for grade 3 stenosis (χ2= 0.0375). 

Our data suggest there is a significant association between segments of spinal cord with at least moderate CS and segments with MS lesions. Further studies to expand our cohort and include CS only control patients are planned.

Authors/Disclosures
Daniel Gratch
PRESENTER
No disclosure on file
David Do, MD (University of Pennsylvania) Dr. Do has nothing to disclose.
Matthew Schindler, MD, PhD (Univeristy of Pennsylvania) Dr. Schindler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapuetics. Dr. Schindler has received personal compensation in the range of $5,000-$9,999 for serving as a 好色先生al Presenter with Annenberg Center.
No disclosure on file
Pouya Khankhanian, MD (Kaiser Dublin) No disclosure on file
Joseph R. Berger, MD, FAAN Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb/Celgene. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle Pharma. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dice Therapeutics. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Gilead. Dr. Berger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck/. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Morphic. Dr. Berger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MAPI. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ExcisionBio. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Population Bio. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Berger has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Assorted .